Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.

This study applied an efficient virtual screening strategy integrating molecular docking with MM-GBSA rescoring to identify diverse human dihydroorotate dehydrogenase (hDHODH) inhibitors. Eighteen compounds with IC(50) values ranging from 0.11 to 18.8 μM were identified as novel hDHODH inhibitors that exhibited overall species-selectivity over Plasmodium falciparum dihydroorotate dehydrogenase (pfDHODH). Compound 8, the most potent one, showed low micromolar inhibitory activity against hDHODH with an IC(50) value of 0.11 μM. Moreover, lipopolysaccharide-induced B-cell assay and mixed lymphocyte reaction assay revealed that most of the hits showed potent antiproliferative activity against B and T cells, which demonstrates their potential application as immunosuppressive agents. In particular, compound 18 exhibited potent B-cell inhibitory activity (IC(50) = 1.78 μM) and presents a B-cell-specific profile with 17- and 26-fold selectivities toward T and Jurkat cells, respectively.

[1]  J. Ruckdeschel,et al.  Multicenter phase II study of brequinar sodium in patients with advanced lung cancer , 2004, Cancer Chemotherapy and Pharmacology.

[2]  K. Jensen,et al.  Insight into the chemistry of flavin reduction and oxidation in Escherichia coli dihydroorotate dehydrogenase obtained by rapid reaction studies. , 2001, Biochemistry.

[3]  J. Clardy,et al.  Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. , 2000, Structure.

[4]  Charles Y. Lin,et al.  DHODH modulates transcriptional elongation in the neural crest and melanoma , 2011, Nature.

[5]  Roy J. Vaz,et al.  Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures. , 2010, Bioorganic & medicinal chemistry letters.

[6]  J. Gummert,et al.  Newer immunosuppressive drugs: a review. , 1999, Journal of the American Society of Nephrology : JASN.

[7]  Pradipsinh K Rathod,et al.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. , 2010, Infectious disorders drug targets.

[8]  P. Chumakov,et al.  Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway , 2010, Proceedings of the National Academy of Sciences.

[9]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[10]  M. Schreier,et al.  Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations. , 1998, Journal of medicinal chemistry.

[11]  J. Kallen,et al.  Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties. , 1999, The Journal of antibiotics.

[12]  Richard A. Friesner,et al.  What role do surfaces play in GB models? A new‐generation of surface‐generalized born model based on a novel gaussian surface for biomolecules , 2006, J. Comput. Chem..

[13]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[14]  R. Baumgartner,et al.  Dual binding mode of a novel series of DHODH inhibitors. , 2007, Journal of medicinal chemistry.

[15]  S. Al-Karadaghi,et al.  Inhibition of Human DHODH by 4‐Hydroxycoumarins, Fenamic Acids, and N‐(Alkylcarbonyl)anthranilic Acids Identified by Structure‐Guided Fragment Selection , 2010, ChemMedChem.

[16]  Pradipsinh K Rathod,et al.  Malarial Dihydroorotate Dehydrogenase , 2002, The Journal of Biological Chemistry.

[17]  K. Memmert,et al.  Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. , 1999, The Journal of antibiotics.

[18]  B. Diamond,et al.  Autoimmune diseases , 2000, Bone Marrow Transplantation.

[19]  Honglin Li,et al.  Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. , 2009, Journal of medicinal chemistry.

[20]  D. Morré,et al.  Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. , 1988, Biochemical pharmacology.

[21]  H. Simmonds,et al.  Pyrimidine pathways in health and disease. , 2005, Trends in molecular medicine.

[22]  J. Clardy,et al.  Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase. , 2006, Bioorganic & medicinal chemistry letters.

[23]  E. Johansson,et al.  Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane‐associated N‐terminal domain , 2004, Protein science : a publication of the Protein Society.

[24]  B. S. Holla,et al.  Synthesis of some new 2,4-disubstituted thiazoles as possible antibacterial and anti-inflammatory agents. , 2003, European journal of medicinal chemistry.

[25]  B. Kirschbaum,et al.  Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans* , 1998, The Journal of Biological Chemistry.

[26]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[27]  Paul D Lyne,et al.  Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.

[28]  C. Heusser,et al.  Aromatic quinolinecarboxamides as selective, orally active antibody production inhibitors for prevention of acute xenograft rejection. , 2001, Journal of medicinal chemistry.

[29]  B. Jaffee,et al.  Side effects of brequinar and brequinar analogues, in combination with cyclosporine, in the rat. , 1998, Toxicology.

[30]  V. Vyas,et al.  Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. , 2011, Mini reviews in medicinal chemistry.

[31]  Li Zhang,et al.  One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation , 2006, Bioorganic & Medicinal Chemistry.

[32]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[33]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[34]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[35]  D. Wirth,et al.  Identification and Characterization of Small Molecule Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2008, Journal of Biological Chemistry.

[36]  A. Boa,et al.  Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase. , 2005, Bioorganic & medicinal chemistry.

[37]  Darrell E Hurt,et al.  Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. , 2006, Acta crystallographica. Section D, Biological crystallography.

[38]  M. Davies,et al.  Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. , 2009, Journal of medicinal chemistry.

[39]  K. Dill,et al.  Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". , 2009, Structure.

[40]  S. Al-Karadaghi,et al.  The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. , 2008, Biochemistry.

[41]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[42]  R. Madhok,et al.  Benefit-Risk Assessment of Leflunomide , 2009, Drug safety.

[43]  B. S. Holla,et al.  Synthesis of some novel 2,4-disubstituted thiazoles as possible antimicrobial agents. , 2008, European journal of medicinal chemistry.

[44]  L. Kramer,et al.  Inhibition of Dengue Virus through Suppression of Host Pyrimidine Biosynthesis , 2011, Journal of Virology.

[45]  W. Knecht,et al.  Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. , 2000, Chemico-biological interactions.

[46]  Pierre Ernst,et al.  Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[47]  N. Rose.  Autoimmune diseases. , 1981, Scientific American.

[48]  N. Kumari,et al.  Synthesis of Some New 2,4‐Disubstituted Thiazoles as Possible Antibacterial and Antiinflammatory Agents. , 2003 .

[49]  R. Jankowsky,et al.  Immunopathology and Infectious Diseases 4 SC-101 , A Novel Small Molecule Dihydroorotate Dehydrogenase Inhibitor , Suppresses Systemic Lupus Erythematosus in MRL-( Fas ) lpr Mice , 2010 .

[50]  D. Thomas,et al.  Divergent evolution of pyrimidine biosynthesis between anaerobic and aerobic yeasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Herrmann,et al.  Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. , 2000, Immunopharmacology.

[52]  V. Simon,et al.  Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis , 2011, Proceedings of the National Academy of Sciences.